Septerna, Inc.
NASDAQ:SEPN · NASDAQ Global Select
-$0.73 today
Vol 0.27M · Avg 0.32M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SEPN · Revenue to Net Income
Key Ratios
Analysis
$72.3M of revenue converted into -$36.0M of net income for the selected period. Gross margin is 99.6% and net margin is -5227.8%, showing how much revenue survives after costs and taxes. EPS is $-0.81, tying the income statement back to per-share earnings.
Income Statement
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $46.0M +4174.5% | $1.1M +611.9% | $151.0K | $888.0M | $1.0B | $809.6M |
| Cost of Revenue | $0 | $0 | $0 | -$1.7B | $344.8M | $725.6M |
| Gross Profit | $46.0M +4174.5% | $1.1M +611.9% | $151.0K | $11.6B | $10.3B | $8.9B |
| Gross Margin | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 26.4% | 45.5% | 9.8% |
| Research & Development | $97.6M +49.4% | $65.3M +81.6% | $36.0M | $1.2B | $378.4M | $983.2M |
| Selling, General & Admin | $29.2M +76.1% | $16.6M +70.3% | $9.7M | $811.0M | $1.4B | $620.6M |
| Operating Expenses | $126.7M +54.8% | $81.9M +4356.7% | -$1.9M | -$15.9B | $3.6B | $5.3B |
| Depreciation & Amortization | $1.6M +14.5% | $1.4M +65.2% | $848.0K | $419.0M | $1.2B | $374.2M |
| EBITDA | -$47.3M +33.3% | -$70.9M -58.6% | -$44.7M | $10.0B | $12.6B | -$15.2B |
| EBITDA Margin | -102.9% +6492.0pp | -6594.9% +23009.1pp | -29604.0% | 14.3% | 10.0% | 5.6% |
| Operating Income | -$80.8M +0.0% | -$80.8M -3995.1% | $2.1M | $9.0B | $10.6B | $12.3B |
| Operating Margin | -175.8% +7342.6pp | -7518.4% -8892.6pp | 1374.2% | 11.2% | 18.7% | 16.6% |
| Interest Income | $19.5M +126.6% | $8.6M +209.3% | $2.8M | $875.4M | $1.3B | -$1.5B |
| Interest Expense | $0 | $0 | $0 | $801.2M | $969.2M | $1.1B |
| Other Income / Expenses | $31.9M +274.5% | $8.5M +205.0% | $2.8M | $368.6M | -$1.6B | -$1.5B |
| Income Before Tax | -$48.9M +32.4% | -$72.3M -1584.2% | $4.9M | $13.9B | -$15.6B | $3.3B |
| Pre-Tax Margin | -106.3% +6618.9pp | -6725.2% -9951.0pp | 3225.8% | 15.4% | 13.3% | 20.8% |
| Income Tax Expense | $12.0K +102.4% | -$498.0K -172.1% | $691.0K | $375.6M | $666.8M | $1.3B |
| Net Income | -$48.9M +31.9% | -$71.8M -1817.7% | $4.2M | $5.1B | $5.0B | $4.9B |
| Net Margin | -106.4% +6572.5pp | -6678.9% -9447.1pp | 2768.2% | 47.3% | 7.4% | 12.4% |
| EPS (Basic) | -$1 +43.0% | -$2 -6732.3% | $0 | $591.2M | $1.2B | $400.8M |
| EPS (Diluted) | -$1 +43.0% | -$2 -6732.3% | $0 | $777.4M | $620.6M | $766.2M |
| Weighted Avg Shares | $44.3M +19.0% | $37.2M +90.8% | $19.5M | $724.2M | $892.2M | $757.8M |
| Weighted Avg Shares (Diluted) | $44.3M +19.0% | $37.2M +90.8% | $19.5M | $566.0M | $319.6M | $1.2B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.58B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.44B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.24B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Arbutus Biopharma Corporation
NASDAQ:ABUS
$883.98M
Kura Oncology, Inc.
NASDAQ:KURA
$852.77M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$735.64M
Prime Medicine, Inc.
NASDAQ:PRME
$564.43M
ProKidney Corp.
NASDAQ:PROK
$263.74M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SEPN generate?
Septerna, Inc. (SEPN) reported $45.95M of revenue in fiscal 2025.
Is SEPN profitable?
Septerna, Inc. (SEPN) reported -$48,879,000.00 of net income, with a net margin of -106.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.